Application of 4D-DIA Quantitative Proteomics

By Carol Hernandez · Published: September 1, 2024

4D-DIA quantitative proteomics is applied when relative protein discovery needs unlabeled data-independent acquisition (DIA) plus ion mobility, commonly on timsTOF platforms that couple PASEF-style scheduling to fragment chromatogram extraction (Meier et al. 2018; Gillet et al. 2012). Typical applications are treatment or disease screens, biofluid cohort discovery, and mechanism studies that need more complete matrices than stochastic DDA while keeping independent enrollment. The valid output remains relative same-protein change under matched prep and QC. 4D-DIA fits when mobility-resolved DIA depth matches the matrix; classical SWATH-style DIA fits when mobility hardware is unavailable; TMT or PRM fits when multiplex labeling or a closed panel is the next experiment.

 

For defined samples, comparison groups, or a specific project objective, see the MtoZ Biolabs Deep DIA Proteomics Service and DIA Quantitative Proteomics Analysis Service for project-specific feasibility and analysis planning.

 

Where 4D-DIA Applications Fit in Practice

4D-DIA is DIA acquisition with ion mobility as an added separation dimension alongside retention time, m/z, and signal intensity. Applications succeed when the study still accepts a relative, unlabeled claim.

 

Application setting What 4D-DIA commonly contributes Design point
Disease or tumor versus control screens Relative proteome matrices with improved peptide discrimination in complex digests Validated diagnostic biomarkers follow a separate assay
Drug or perturbation response Treatment-linked relative protein changes across independent cultures or tissues Absolute target occupancy uses standards
Biofluid cohort discovery Flexible enrollment under matched unlabeled prep Low-abundance candidates follow depth and QC
Pathway or mechanism follow-up Broader relative coverage than many DDA missing-value matrices Pathway activity is a later interpretation
PTM-focused relative panels Mobility-aided discrimination after enrichment chemistry Site stoichiometry uses a calibrated assay

Application scenes for 4D-DIA including biomarker screens, drug-response proteomes, biofluid cohorts, and PTM-enriched relative panels

Figure 1. 4D-DIA applications center on relative unlabeled discovery in complex samples.

 

Disease, drug, and PTM use cases are read as relative DIA discovery under the stated prep and QC.

 

4D-DIA Versus Classical DIA or SWATH in Applied Work

Classical DIA and SWATH-style methods already fragment scheduled precursor windows and extract peptide peak groups for relative quantification (Gillet et al. 2012). 4D-DIA adds ion-mobility separation, often implemented with PASEF on timsTOF systems, to reduce co-eluting interference and support deeper matrices in complex samples (Meier et al. 2018). The application family remains unlabeled relative discovery. Hardware and software readiness decide whether a project should use mobility-resolved DIA or a classical DIA/SWATH route.

 

Comparison of 4D-DIA with ion mobility versus classical SWATH-style DIA without mobility for relative unlabeled quantification

Figure 2. 4D-DIA applications keep the DIA relative claim; ion mobility is an added discrimination layer.

 

For principle-level framing, see Principle of 4D-DIA Quantitative Proteomics. For design trade-offs, see Advantages and Disadvantages of 4D-DIA Quantitative Proteomics. For workflow context, see 4D Label-Free Quantitative Proteomics Workflow: From Sample Prep to Data Interpretation. For DIA versus SWATH basics, see What Is DIA and SWATH? Understanding Data-Independent Acquisition in Proteomics.

 

Judgment Criteria: When 4D-DIA Applications Fit

 

Study need 4D-DIA application often fits Design point
Claim Relative same-protein discovery across independent runs Absolute concentration or diagnostic cutoff
Sample plan Unlabeled enrollment may continue over time All contrasts must share one TMT plex
Matrix Complex tissues or biofluids benefit from mobility-aided DIA Simple purified proteins needing intact or targeted assays
Platform timsTOF or equivalent mobility-DIA capacity is available Only classical DIA/SWATH hardware is available
Follow-up Discovery list may later move to PRM or AQUA Closed shortlist already needs amount units now

4D-DIA applications fit when mobility-resolved unlabeled DIA depth matches the matrix and QC plan. Classical DIA or SWATH-style workflows fit when ion-mobility hardware is unavailable but DIA completeness is still needed. TMT fits when same-run multiplex ratios match a frozen kit. PRM, MRM, or AQUA fits when a closed peptide list needs tighter confirmation or calibrated amount.

Decision flow for 4D-DIA applications versus classical DIA or SWATH, TMT multiplex, and targeted absolute routes

Figure 3. Choose 4D-DIA applications from the relative unlabeled claim and mobility-DIA readiness; change route when multiplex labeling or absolute panels dominate.

 

For DIA advantage lists, see Advantages and Disadvantages of DIA in Protein Quantification. For SWATH versus DDA selection, see SWATH-MS vs DDA-MS: Which Technique Is Suitable for Your Research?. For labeling versus unlabeled selection, see TMT vs Label Free Quantitative Proteomics.

 

Planning a 4D-DIA Application

Ion mobility is read together with matched prep and run-order control. Completeness and accuracy remain separate claims. Window or mobility-group interference can still distort peak groups if FDR and shape filters are weak. Ordinary 4D-DIA intensities remain relative unless stable isotope-labeled standards and calibration are added. Pathway enrichment from a differential list shows overrepresentation relative to the quantified background. PTM applications inherit enrichment chemistry; site occupancy uses a calibrated assay.

 

Typical application patterns:

  • Tumor-versus-adjacent or disease-versus-control relative screens in complex tissues.

  • Drug-treatment proteome responses in cells or tissues with independent unlabeled injections.

  • Plasma, serum, or other biofluid discovery cohorts with flexible enrollment.

  • Discovery shortlists later confirmed by PRM, MRM, or AQUA when amount or tighter ion control is required.

 

Diagnostic cutoffs and companion-diagnostic claims follow a separately validated assay framework when that framework is already in place.

 

Once sample type, mobility-DIA capacity, and the relative claim are defined, the project can be scoped as a 4D-DIA application study. Researchers can review the MtoZ Biolabs Deep DIA Proteomics Service for sample evaluation and workflow planning. For unlabeled DIA service framing, see Label-Free DIA Quantitative Proteomics.

 

Frequently Asked Questions

1. What applications is 4D-DIA best known for?

Relative unlabeled discovery in complex tissues, drug-response screens, and biofluid cohorts where mobility-aided DIA depth is available.

 

2. How does 4D-DIA relate to classical SWATH?

Both are DIA-family methods. 4D-DIA adds ion mobility; SWATH-style workflows historically emphasize sequential-window library extraction without requiring mobility hardware.

 

3. Can 4D-DIA applications report absolute protein concentration?

Absolute amount needs matched standards and calibration on a closed panel. Ordinary 4D-DIA intensities are relative.

 

4. How does ion mobility relate to sample prep?

Unmatched digestion, detergents, and confounded run order still create artifacts that software cannot fully repair. Prep and mobility are planned together.

 

5. When should a 4D-DIA application move to PRM or TMT?

Move to PRM or AQUA when a closed shortlist needs tighter confirmation or amount units. Move to TMT when same-run multiplex ratios fit a frozen plex better than independent unlabeled runs.

Reference

  1. F. Meier, A.-D. Brunner, S. Koch, et al. (2018). Online Parallel Accumulation-Serial Fragmentation (PASEF) enables fast and high capacity proteome analysis. Mol. Cell. Proteomics, 17, 2053-2067. https://doi.org/10.1074/mcp.TIR118.000900
  2. L.C. Gillet, P. Navarro, S. Tate, et al. (2012). Targeted data extraction of the MS/MS spectra generated by data-independent acquisition: a new concept for consistent and accurate proteome analysis. Mol. Cell. Proteomics, 11, O111.016717. https://doi.org/10.1074/mcp.M111.016717

Support Documents

DIA-Based Quantitative Proteomics Service

Discover how DIA-based quantitative proteomics can support comprehensive protein profiling and comparative studies by downloading our service overview.

Protein Quantification for Deeper Discovery

Gain a clearer understanding of protein quantification approaches and their applications in studying protein abundance changes by downloading our detailed brochure.

Submit the form below to download the
This checkbox is required
* I agree to receive other communications from MtoZ Biolabs, which may contain technical or marketing information. You can unsubscribe from thlese communications at any time.
SUBMIT
 

How to Order

How to Order
Request a Quote

Request a Project Quote

Please complete the required fields below. We will review your information and respond with a tailored recommendation.

Project inquiry

Fields marked with * are required for quote review.

Secure inquiry · No obligation
Required Information

Your information will be used only to respond to your inquiry.

Submit Inquiry